about
The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors: a post hoc exploratory analysis of recombinant activated factor VII data from thPhysical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports.Beyond stopping the bleed: short-term episodic prophylaxis with recombinant activated factor FVII in haemophilia patients with inhibitors.Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis.Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay.Managing Haemophilia for Life: 5th Haemophilia Global Summit.
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Prophylaxis in real life scenarios.
@en
type
label
Prophylaxis in real life scenarios.
@en
prefLabel
Prophylaxis in real life scenarios.
@en
P2860
P356
P1433
P1476
Prophylaxis in real life scenarios.
@en
P2093
C Broderick
C M Kessler
P2860
P304
P356
10.1111/HAE.12425
P478
20 Suppl 4
P577
2014-05-01T00:00:00Z